What Is Treatment-Resistant Depression? A Utah Practitioner's Guide to 7 Next-Step Options
Treatment-resistant depression (TRD) is major depressive disorder that has not responded to at least two adequate trials of antidepressants. It affects roughly 30% of patients with depression. If you are in this group, evidence-based next steps include ketamine therapy, esketamine (Spravato), functional medicine evaluation, nutritional psychiatry, transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), and structured psychotherapy paired with medication review. At Black Psychiatry in Utah, Christopher Black, APRN, PMHNP-BC, specializes in patients whose depression has not improved with standard care.
What treatment-resistant depression actually is
Treatment-resistant depression is not a separate diagnosis. It is a clinical label applied when major depressive disorder fails to remit after at least two adequate trials of antidepressant medication from different classes, each prescribed at a therapeutic dose for a sufficient duration (typically 6 to 8 weeks). The landmark STAR*D trial, published in the American Journal of Psychiatry, found that only about 30 to 37% of patients achieved remission with their first antidepressant. Remission rates dropped with each subsequent step: 30.6% at step two, 13.7% at step three, and 13% at step four.
In plain language: if you have tried two antidepressants at full dose for full duration and you still feel depressed, you are not failing treatment. The treatment is failing you, and there are next steps that the standard primary-care pathway does not always offer. A Psychiatric-Mental Health Nurse Practitioner who specializes in integrative care can re-evaluate the diagnosis, the dosing, the medication choice, and the underlying biology before you spend another six months on a medication that is unlikely to work.
How common is treatment-resistant depression in 2026
Roughly one in three adults with major depression meets criteria for treatment-resistant depression. According to a 2026 industry analysis by Innerwell, about 35% of people with major depression do not respond to standard antidepressants. The burden is substantial: TRD is associated with higher rates of suicidality, cardiovascular disease, and reduced work capacity compared to depression that responds to first-line treatment.
Utah carries a heavier mental health load than most states. Mental Health America ranked Utah #46 out of all states in 2024 for the combination of high depression and anxiety prevalence and low access to care. A 2022 Kaiser Family Foundation survey found that nearly 36% of Utah adults reporting symptoms of anxiety or depression could not get the counseling or therapy they needed, compared to 28% nationally. For Utahns with treatment-resistant depression, the access gap is wider still, because the practitioners trained in advanced options like ketamine therapy and functional medicine are concentrated in a small number of clinics.
The 7 next-step options for treatment-resistant depression
Below is a side-by-side comparison of the seven options most commonly considered for treatment-resistant depression in 2026. Each has different evidence, time-to-effect, and access profile in Utah. The right next step depends on your specific history, comorbidities, and goals, which is why a thorough re-evaluation by a Psychiatric-Mental Health Nurse Practitioner is the first move.
| Option | Mechanism | Time to Effect | Evidence Strength | Available at Black Psychiatry |
|---|---|---|---|---|
| IV Ketamine Therapy | NMDA receptor antagonist, promotes neuroplasticity | Hours to days | Non-inferior to ECT per NEJM 2023 trial | Yes |
| Esketamine (Spravato) | Intranasal S-ketamine, FDA-approved for TRD | Days to weeks | FDA-expanded standalone indication Jan 2025 | Referral coordination |
| Medication re-evaluation | Switch, augment, or combine antidepressants | 4 to 8 weeks | Strong (STAR*D data) | Yes |
| Functional medicine workup | Identify metabolic, hormonal, inflammatory drivers | Variable | Emerging, especially for TRD subtypes | Yes |
| Nutritional psychiatry | Gut-brain axis, targeted nutrient correction | Weeks to months | Strong observational, growing RCT base | Yes |
| Transcranial magnetic stimulation (TMS) | Magnetic stimulation of prefrontal cortex | 4 to 6 weeks | FDA-approved, strong evidence | Referral coordination |
| Electroconvulsive therapy (ECT) | Controlled seizure under anesthesia | 1 to 3 weeks | Gold standard for severe TRD | Referral coordination |
How ketamine therapy works for treatment-resistant depression
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist. Unlike SSRIs and SNRIs, which raise monoamine neurotransmitters and take weeks to work, ketamine acts on the glutamate system and can produce measurable improvement in depressive symptoms within hours. A 2023 New England Journal of Medicine trial found that IV ketamine was non-inferior to electroconvulsive therapy (ECT) for nonpsychotic treatment-resistant major depression, with response defined as at least a 50% reduction in symptom severity.
A nationwide cohort study published in 2023, drawing on electronic health records from 93 million patients and 321,367 with treatment-resistant depression, found that ketamine prescription was associated with significantly decreased risk of suicidal ideation at 7, 30, 90, 180, and 270 days compared to other common antidepressants. At Black Psychiatry, ketamine therapy is delivered as controlled injections paired with integration therapy, the structured clinical conversations that help patients translate the neuroplastic window opened by ketamine into durable behavioral and cognitive change.
The role of functional medicine and nutritional psychiatry
Standard psychiatric care treats depression as primarily a brain-chemistry problem. Functional and nutritional psychiatry expand the lens to include the gut microbiome, inflammatory markers, thyroid function, vitamin D status, B12, folate, iron, omega-3 levels, sleep architecture, and metabolic health. A 2025 review in Frontiers in Immunology synthesized evidence that the microbiota-gut-brain axis is a critical determinant in depression, with gut dysbiosis influencing neuroendocrine, neuroimmune, and metabolic pathways involved in mood regulation.
For treatment-resistant cases, this matters because an undiagnosed thyroid issue, persistent inflammation, or a severe nutrient deficiency can blunt the response to any antidepressant, no matter how many medication trials you go through. Christopher Black, APRN, PMHNP-BC, integrates functional medicine workups into the initial evaluation at Black Psychiatry, identifying root causes that other pathways might miss.
When to seek a second opinion in Utah
Patients should consider a second opinion if any of the following apply: two or more antidepressant trials without remission, recurrence within a year of stopping medication, intolerable side effects that have driven multiple medication changes, suicidal ideation that has persisted despite treatment, or a sense that the original diagnosis does not fit the actual experience. Utah's psychiatric provider shortage makes second opinions hard to access, but telehealth has changed the equation.
Black Psychiatry offers telehealth appointments across Utah with next-day availability in most cases. The initial 120-minute consultation costs $850 for self-pay patients. Cigna and Aetna are accepted. The first appointment includes a thorough review of past medications, current symptoms, functional medicine markers worth investigating, and a candid discussion of which next-step options are most likely to fit the patient's specific situation.
What to expect at your first appointment with Black Psychiatry
The initial consultation runs 120 minutes. It is intentionally long, because treatment-resistant depression cases require a full history rather than a 15-minute medication check. Christopher Black, APRN, PMHNP-BC, will review every antidepressant tried, the dose, the duration, the response, and the side effects. He will discuss family psychiatric history, sleep, nutrition, physical activity, substance use, and any prior diagnoses worth re-examining. Functional medicine testing may be recommended based on what surfaces in the history.
From that single appointment, most patients leave with a written plan that names the next step clearly: a medication adjustment, a referral for TMS or ECT if appropriate, a ketamine therapy protocol if indicated, or a functional medicine workup to clarify the underlying drivers. The goal of Black Psychiatry is not to add another medication to the stack. It is to find the actual cause of the resistance and treat that.
Telehealth across Utah. Next-day appointments. Initial 120-minute consultation $850. Cigna and Aetna accepted.
Schedule an appointment with Christopher Black, APRN, PMHNP-BC
Frequently Asked Questions
What qualifies as treatment-resistant depression?
Treatment-resistant depression is generally defined as major depressive disorder that has not remitted after at least two adequate trials of antidepressants from different classes, each prescribed at a therapeutic dose for at least 6 to 8 weeks. Some clinical definitions require three failed trials.
Does ketamine therapy work for treatment-resistant depression?
Clinical evidence is strong. A 2023 New England Journal of Medicine trial found IV ketamine non-inferior to electroconvulsive therapy for nonpsychotic treatment-resistant major depression. Improvement can occur within hours to days, compared to weeks for SSRIs. Black Psychiatry offers ketamine therapy with integration sessions in Utah.
Is Christopher Black a psychiatrist?
Christopher Black is a board-certified Psychiatric-Mental Health Nurse Practitioner (APRN, PMHNP-BC), not a physician. PMHNPs in Utah have full prescriptive authority and provide psychiatric evaluation, medication management, and psychotherapy.
Does Black Psychiatry accept insurance?
Black Psychiatry accepts Cigna and Aetna. Self-pay is also available; the initial 120-minute consultation costs $850.
How fast can I get a first appointment?
Black Psychiatry offers next-day appointments in most cases via telehealth across Utah. You can schedule directly online or by calling (801) 361-2255.
Sources Referenced
- STAR*D Trial — American Journal of Psychiatry 2006
- Ketamine vs. ECT — New England Journal of Medicine 2023
- Ketamine and Suicidal Ideation in TRD — Nationwide Cohort, 2023
- Mental Health Statistics 2026 — Innerwell
- Utah Mental Health Access Data — Kaiser Family Foundation via Axios, 2025
- Microbiota-Gut-Brain Axis in Depression — Frontiers in Immunology 2025
This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Reading this content does not establish a patient-provider relationship. If you are experiencing a mental health emergency, call 988 or go to your nearest emergency room. For personalized care, schedule an appointment with Christopher Black, APRN, PMHNP-BC at Black Psychiatry.
Hello, World!
